Metlife Investment Management Reduces $2M in Bruker Corporation ($BRKR)
Key Points
- Metlife Investment Management changed its Bruker Corporation ($BRKR) stake by 5.44% last quarter, cutting to 475,733 shares worth $28.63 million.
- $BRKR last traded around $60.18.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Metlife Investment Management trimmed its position in Bruker Corporation ($BRKR) by 5.44% during the most recent quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 475,733 shares of Bruker Corporation after selling 27,366 shares during the quarter. Metlife Investment Management's holdings in Bruker Corporation were worth $28.63 million as of its most recent filing.
Bruker Corporation Stock Up 5.4%
Shares of Bruker Corporation ($BRKR) traded around $60.18 on Saturday, up 5.4% for the day.
Bruker Corporation Earnings
Bruker Corporation Dividend
Analysts Set New Price Targets
About Bruker Corporation
Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions. It operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies. The company offers magnetic resonance spectroscop, preclinical imaging, biopharma and applied, services and lifecycle support, integrated data solution, and automation; life science tools; innovative nuclear magnetic resonance (NMR) and electron paramagnetic resonance (EPR) products; solutions for in-vivo processes and drug discovery; aftermarket solutions; solutions for lab automation and digitalization; mass spectrometry solution and test kits, DNA test strips, and fluorescence-based PCR technologies; genotype and fluorotype molecular diagnostics kits; and research, analytical, and process analysis instruments and solutions. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; services for transcriptional profiling and multiomic analysis; superconducting materials, such as metallic low temperature superconductors; multifilament round and rectangular LTS wires in both monolithic and wire-in-channel formats; designs and manufactures Cuponal; metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. Bruker Corporation was founded in 1960 and is headquartered in Billerica, Massachusetts.
Get Bruker Corporation alerts
New 13F filings, insider trades, and analyst moves on $BRKR, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.